Physiomics plc announced that it has entered into a strategic collaboration with the Medicines Discovery Catapult ("MDC"). Physiomics will be part of the MDC's "Virtual R&D" network of advisors and available to provide advice to the many small biotechnology companies supported by the MDC from its Alderley Park base. Under the terms of the agreement the MDC will introduce Physiomics to selected potential clients and in return will receive a small commission on the value of any service contracts arising from such introductions. Physiomics offers a range of services including its proprietary Virtual Tumour technology to predict the effect of oncology drugs and improve the success rate of oncology R&D. It works with companies ranging from start-ups to some of the pharmaceutical companies and has experience in a wide range of treatments, including radiation, DNA repair inhibitors and immune therapies. The MDC was established by Innovate UK (part of UK Research & Innovation) to support the discovery and evaluation of medicines by providing access to expert technical capabilities, equipment and other resources required to take new ideas from concept to reality. Its Virtual R&D group supports UK-based biotech companies by conducting diligence on their programs as well as through project management and by connecting them to a variety of expert consultants and service providers.